Biotech

All Articles

Molecular Partners changes AML trial over 'suboptimal direct exposure'

.Molecular Companions has recognized "suboptimal exposure" to its tetra-specific T-cell engager as t...

Despite mixed market, a financial backing revival might be can be found in Europe: PitchBook

.While the biotech financial investment performance in Europe has slowed down relatively adhering to...

8 months after a $213M fundraise, gene editor Volume creates decreases

.After increasing $213 million in 2023-- some of the year's largest private biotech rounds-- Volume ...

BioMarin creates exec group with biotech vets-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of significant management hirings, firings a...

Biopharma Q2 VC attacked highest level given that '22, while M&ampA slowed down

.Venture capital financing in to biopharma cheered $9.2 billion throughout 215 sell the second fourt...

Bicara, Zenas seek IPOs to press late-phase assets towards market

.Bicara Therapeutics and also Zenas Biopharma have provided fresh motivation to the IPO market along...

Genentech to close cancer cells immunology study division

.Genentech is going to shut its cancer cells immunology study division, as well as system mind and a...

Kezar loses strong lump but to confirm its really worth in period 1 trial

.Kezar Lifestyle Sciences is dropping its unpromising period 1 strong tumor medication as the biotec...

Acelyrin goes down izokibep, lets go 3rd of staff

.Even with izokibep keeping its own newfound winning streak in the center, Acelyrin is actually no m...

Rivus' phase 2 obesity-related heart failure test reaches endpoint

.Rivus Pharmaceuticals has plumped up the potential customers of its own fat-busting, muscle-sparing...